Edwards Lifesciences Corporation
NYON, Switzerland, April 4, 2011 - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the
science of heart valves and haemodynamic monitoring, announced the results of
a pivotal clinical study of high-risk surgical patients with severe aortic
stenosis treated in Cohort A of The PARTNER Trial.
IRVINE, California, November 16, 2010 - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the
science of heart valves and hemodynamic monitoring, announced that in
addition to the improved survival seen in inoperable aortic stenosis patients
treated with the Edwards SAPIEN transcatheter heart valve in The PARTNER
Trial, a newly released analysis of the same patients shows that they also
experienced substantially better quality of life.
